Advertisement
UK markets close in 1 hour 53 minutes
  • FTSE 100

    8,188.58
    -26.90 (-0.33%)
     
  • FTSE 250

    20,362.74
    -134.66 (-0.66%)
     
  • AIM

    785.36
    -2.00 (-0.25%)
     
  • GBP/EUR

    1.1833
    -0.0001 (-0.01%)
     
  • GBP/USD

    1.2789
    -0.0011 (-0.08%)
     
  • Bitcoin GBP

    53,242.15
    -1,004.15 (-1.85%)
     
  • CMC Crypto 200

    1,427.17
    +14.22 (+1.01%)
     
  • S&P 500

    5,430.76
    +9.73 (+0.18%)
     
  • DOW

    38,573.39
    -138.82 (-0.36%)
     
  • CRUDE OIL

    78.71
    +0.21 (+0.27%)
     
  • GOLD FUTURES

    2,333.90
    -20.90 (-0.89%)
     
  • NIKKEI 225

    38,720.47
    -156.24 (-0.40%)
     
  • HANG SENG

    18,112.63
    +174.79 (+0.97%)
     
  • DAX

    18,420.76
    -210.10 (-1.13%)
     
  • CAC 40

    7,764.22
    -100.48 (-1.28%)
     

Medigene AG to participate at BIO International in Boston

Medigene AG
Medigene AG

Planegg/Martinsried, May 30, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 in Boston, MA.

BIO International Convention
https://www.bio.org/events/bio-international-convention

Date: June 5-8, 2023,
Location: Boston, MA

Medigene’s management team will be available for one-on-one meetings at the event. Please contact Sandya von der Weid of LifeSci Advisors at svonderweid@lifesciadvisors.com to schedule a meeting.

ADVERTISEMENT

---  end of press release  ---

About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com

About Medigene’s End-To-End Platform
Medigene’s immunotherapies help activate the patient’s own defense mechanisms by harnessing T cells in the battle against cancer. Medigene’s end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class TCR-T therapies. The platform includes multiple product enhancement technologies, (e.g. PD1-41BB Switch Receptor, CD40L-CD28 Switch Receptor, Precision Pairing) and development optimization technologies (e.g. Allogeneic-HLA (Allo-HLA) TCR Priming) to aid the development of differentiated TCR-T therapies. Partnerships with multiple companies including BioNTech, 2seventy bio, and Hongsheng Sciences, continue to validate the platform’s assets & technologies.

Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com

LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.